Solu is building a bacterial DNA database, enabling the analysis, monitoring, and control of antibiotic-resistant bacteria. Its software makes it easier to understand, detect, and prevent the spread of antibiotic resistance and enables the development of new treatment methods against resistant bacteria. The company is collaborating with top international universities, including Stanford University and the University of Hamburg, which use Solu's product in their research on antibiotic resistance. In the future, Solu aims to build a pathogen DNA library to collect all pathogen data in real-time and can also model their evolution and identify new health-threatening pathogens more effectively.
Key people 🧑🤝🧑
- Solving the problem: Antibiotic resistance is a major concern worldwide, and it has seen some acceleration in recent years. According to studies, antibiotic resistance directly caused over one million deaths worldwide in 2019, and nearly five million people died from bacterial infections that are resistant to antibiotics. Solu is building an extensive pathogen DNA library in order to prevent antibiotic resistance via "better research and faster identification." 🔗
- It's fast: Solu is the fastest way to perform 90% of routine workflows for bacteria, helping researchers get their next paper out faster.
- Bold goal: Solu's technology has potential to avoid unnecessary deaths from resistant infections. With better understanding of pathogens, faster diagnostics, and robust surveillance, Solu paves the way for developing new therapies, such as antibiotics, bacteriophages and antitoxin agents.
- Collaborating with top universities: Solu has started collaborating with top international universities, including Stanford University and the University of Hamburg, which use Solu's product in their research on antibiotic resistance.
In the news 📰
Significant problems can be solved by bringing new technology bravely into existing industries. Solu combats antibiotic resistance with big data and user-friendliness. The team's courage to tackle a global challenge, along with their ambition and significant partnerships, impressed us. We are excited to support Solu's team early on in developing their ground-breaking solution.
— Timo Ahopelto, founding partner of Lifeline Ventures 🔗
Last update: June 28, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more